Nephros Announces Financial Results for Quarter Ended March 31, 2026
Rhea-AI Summary
Nephros (Nasdaq: NEPH) reported Q1 2026 results: net revenue $5.2M (up 7% YoY) and net income $0.14M. Core programmatic revenue rose 23% YoY. Gross margin fell to 57% from 65% due to tariffs, FX headwinds, and revenue mix shifts. Cash was ~$4.0M; company remains debt free.
Positive
- Net revenue increased to $5.2M (7% YoY)
- Core programmatic revenue grew 23% year‑over‑year
- Company remains debt free with $4.0M cash
Negative
- Gross margin declined by ~8 percentage points to 57%
- Adjusted EBITDA fell to $206K from $667K (≈69% decline)
- Tariffs and weaker U.S. dollar raised product costs by ~$200K
News Market Reaction – NEPH
In the May 8 session, NEPH gained 8.98%, reflecting a notable positive market reaction. Argus tracked a peak move of +26.1% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 4.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | FY25 earnings | Positive | -7.9% | Record 2025 revenue and profits with margin pressure from tariffs highlighted. |
| Nov 06 | Q3 2025 earnings | Positive | -11.5% | Strong Q3 growth, highest programmatic sales, fourth consecutive profitable quarter. |
| Aug 07 | Q2 2025 earnings | Positive | +35.0% | Q2 revenue up 36% and third straight profitable quarter with margin improvement. |
| Nov 07 | Q3 2024 earnings | Positive | +3.9% | First profitable quarter with improved gross margins and higher Adjusted EBITDA. |
| Aug 08 | Q2 2024 earnings | Neutral | -8.2% | Revenue decline but programmatic growth and narrowed loss with better Adjusted EBITDA. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases often highlight strong revenue and programmatic growth, but short-term price reactions have been mixed, including both sharp gains and notable selloffs.
Over recent earnings cycles, Nephros has reported growing net revenue and a transition to consistent profitability, with multiple quarters of positive net income and expanding programmatic sales. Prior updates cited record fiscal 2025 results with $18.8M revenue, strong Q2 and Q3 2025 growth, and margin impacts from tariffs. Price reactions to these earnings ranged from double-digit gains to notable declines, indicating that investors have focused not only on growth but also on margin trends and cost pressures. Today’s Q1 2026 report continues the theme of revenue growth alongside margin compression drivers.
Key Terms
adjusted ebitda financial
gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
First-Quarter Net Revenue Growth of
SOUTH ORANGE, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the first quarter ended March 31, 2026.
Financial Highlights
- Net revenue was
$5.2 million , compared to$4.9 million in the first quarter of 2025, up7% - Net income was
$140,000 , compared to a net income of$558,000 in the first quarter of 2025 - Adjusted EBITDA was
$206,000 , compared to$667,000 in the first quarter of 2025
“Q1 2026 represents another important milestone for Nephros, as we exceeded
Banks continued, “While we are very pleased with the top-line growth, gross margins in the quarter were impacted by several external and mix-related factors. U.S. tariffs accounted for approximately
Banks added, “We also saw a higher proportion of revenue coming from our commercial segment, which carries a lower gross margin than our core infection control products. Importantly, this shift reflects intentional expansion into new markets such as ice machines, drinking fountains, and other high-use applications. While this mix impacts margins in the near term, it significantly expands our addressable market and supports long-term growth.”
Commenting on the broader outlook, Banks said, “We remain confident in the underlying strength of our business. Our programmatic model continues to drive consistent reorder activity, and we are seeing increasing traction from our installation, replacement, and education initiatives. We believe these efforts are strengthening customer relationships and improving long-term visibility.”
Banks concluded, “We are building a larger, more durable business. Near-term margin variability driven by external factors and growth investments does not change the trajectory. With continued expansion in key markets such as New York and Puerto Rico, and increasing contribution from our installation, replacement, and education initiatives, we are well positioned to drive both revenue growth and margin expansion moving forward.”
Financial Performance for the Quarter Ended March 31, 2026
Net revenue for the three months ended March 31, 2026, and 2025 was
Cost of goods sold for the first quarter of 2025 was
Gross margin for the first quarter of 2026 was
Selling, general and administrative expenses for the first quarter of 2026 were approximately
Research and development expenses for the first quarter of 2026 were approximately
Depreciation and amortization expenses for the first quarter of 2026 were approximately
Net income for the first quarter of 2026 was
Adjusted EBITDA for the first quarter 2026 was approximately
As of March 31, 2026, Nephros had cash and cash equivalents of approximately
Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures
Adjusted EBITDA is calculated by taking net income (loss) calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all interest-related expenses and income, tax-related expenses and income, and non-cash items, including depreciation, amortization, non-cash inventory write-offs, and non-cash compensation. The following tables present a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for the first quarter of the 2026 fiscal year:
| (unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2026 | 2025 | |||||
| (in $ thousands) | ||||||
| Net income | 140 | 558 | ||||
| Adjustments: | ||||||
| Depreciation of property and equipment | 11 | 17 | ||||
| Amortization of other assets | 16 | 23 | ||||
| Interest income | (32 | ) | (13 | ) | ||
| Non-cash stock-based compensation | 60 | 76 | ||||
| Non-cash inventory impairments | 11 | 6 | ||||
| Adjusted EBITDA Income | 206 | 667 | ||||
Nephros believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to Nephros’ financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros’ financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA. To compensate for these limitations, management presents Adjusted EBITDA in connection with net income, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA to net income and not to rely on any single financial measure to evaluate the business.
Conference Call Today at 4:30pm Eastern Time
Nephros will host a conference call today at 4:30pm ET, during which management will discuss Nephros’ financial results and provide a general business overview.
Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285
Upon joining, please ask to be joined into the Nephros conference call.
An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
Alternatively, a replay of the call may be accessed until May 14th, 2026 at 1 (855) 669-9658 or 1 (412) 317-0088 for international callers and entering replay access code: 1329051.
About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within healthcare and commercial markets, offering both proactive and emergency solutions for water management.
For more information about Nephros, please visit nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected future business, revenue and gross margin growth and the timing of such growth, the effect of new regulations on future revenue growth, the expected competitive advantages and anticipated impact of new product offerings and market expansions, Nephros’ ability to obtain refunds for 2025 U.S. tariffs and to otherwise mitigate the impact of U.S. tariffs in the future, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ ability to further develop its sales organization and realize increased revenues, the extent to which financial results based on emergency response sales can be outside Nephros’ control, the extent to which U.S. tariffs may increase our expenses, inflationary factors and other economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this release, and Nephros does not undertake any responsibility to update any forward-looking statements that it makes, except as may be required by law.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
robert.banks@nephros.com
| NEPHROS, INC. | ||||||||
| BALANCE SHEETS | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| ASSETS | March 31, 2026 | December 31, 2025 | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,018 | $ | 5,400 | ||||
| Accounts receivable, net | 3,521 | 2,414 | ||||||
| Inventory | 3,619 | 3,232 | ||||||
| Prepaid expenses and other current assets | 338 | 177 | ||||||
| Total current assets | 11,496 | 11,223 | ||||||
| Property and equipment, net | 95 | 106 | ||||||
| Lease right-use-of assets | 928 | 1,021 | ||||||
| Intangible assets, net | 310 | 318 | ||||||
| Goodwill | 759 | 759 | ||||||
| License and supply agreement, net | 156 | 164 | ||||||
| Other assets | 50 | 50 | ||||||
| TOTAL ASSETS | $ | 13,794 | $ | 13,641 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 1,463 | 914 | ||||||
| Accrued expenses | 662 | 1,462 | ||||||
| Current portion of lease liabilities | 402 | 391 | ||||||
| Total current liabilities | 2,527 | 2,767 | ||||||
| Lease liabilities, net of current portion | 566 | 672 | ||||||
| TOTAL LIABILITIES | 3,093 | 3,439 | ||||||
| STOCKHOLDERS' EQUITY: | ||||||||
| Preferred stock, $.001 par value; 5,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | - | - | ||||||
| Common stock, $.001 par value; 40,000,000 shares authorized at March 31, 2026 and December 31, 2025; 10,843,493 and 10,644,268 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 11 | 11 | ||||||
| Additional paid-in capital | 153,688 | 153,329 | ||||||
| Accumulated deficit | (142,998 | ) | (143,138 | ) | ||||
| TOTAL STOCKHOLDERS' EQUITY | 10,701 | 10,202 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 13,794 | $ | 13,641 | ||||
Earning
| NEPHROS, INC. | ||||||||
| STATEMENTS OF OPERATIONS | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Net revenue: | ||||||||
| Product revenues | $ | 5,040 | $ | 4,706 | ||||
| Royalty and other revenues | 172 | 171 | ||||||
| Total net revenues | 5,212 | 4,877 | ||||||
| Cost of goods sold | 2,219 | 1,723 | ||||||
| Gross margin | 2,993 | 3,154 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | 2,521 | 2,254 | ||||||
| Research and development | 346 | 295 | ||||||
| Depreciation and amortization | 29 | 39 | ||||||
| Total operating expenses | 2,896 | 2,588 | ||||||
| Operating income | 97 | 566 | ||||||
| Other income (expense): | ||||||||
| Interest income | 32 | 13 | ||||||
| Other income (expense) net | 11 | (21 | ) | |||||
| Total other income (expense): | 43 | (8 | ) | |||||
| Net income | $ | 140 | $ | 558 | ||||
| Net income per common share, basic | $ | 0.01 | $ | 0.05 | ||||
| Net income per common share, diluted | $ | 0.01 | $ | 0.05 | ||||
| Weighted average common shares outstanding, basic | 10,650,819 | 10,600,350 | ||||||
| Weighted average common shares outstanding, diluted | 10,990,904 | 10,615,766 | ||||||
